DOP2020000250A - Compuestos antagonistas de la pcsk9 - Google Patents
Compuestos antagonistas de la pcsk9Info
- Publication number
- DOP2020000250A DOP2020000250A DO2020000250A DO2020000250A DOP2020000250A DO P2020000250 A DOP2020000250 A DO P2020000250A DO 2020000250 A DO2020000250 A DO 2020000250A DO 2020000250 A DO2020000250 A DO 2020000250A DO P2020000250 A DOP2020000250 A DO P2020000250A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- compounds
- pcsk9
- formula
- antagonist compounds
- conditions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Abstract
Se describen compuestos de Fórmula I, o una sal de los mismos: Formula I, donde A, B, D, X, R1, R2 y R8 son como se definen en la presente solicitud, compuestos que tienen propiedades para antagonizar PCSK9. También se describen formulaciones farmacéuticas que comprenden los compuestos de Fórmula I o sus sales, y procedimientos para la fabricación de medicamentos útiles para tratar enfermedades cardiovasculares y condiciones relacionadas con la actividad de PCSK9, por ejemplo, aterosclerosis, hipercolesterolemia, enfermedad cardíaca coronaria, síndrome metabólico, síndrome coronario agudo o enfermedad cardiovascular relacionada y condiciones cardiometabólicas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862687913P | 2018-06-21 | 2018-06-21 | |
PCT/US2019/038155 WO2019246349A1 (en) | 2018-06-21 | 2019-06-20 | Pcsk9 antagonist compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2020000250A true DOP2020000250A (es) | 2021-02-28 |
Family
ID=67263083
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2020000250A DOP2020000250A (es) | 2018-06-21 | 2020-12-17 | Compuestos antagonistas de la pcsk9 |
Country Status (25)
Country | Link |
---|---|
US (2) | US11427616B2 (es) |
EP (1) | EP3810626A1 (es) |
JP (2) | JP7112531B2 (es) |
KR (1) | KR20210024035A (es) |
CN (1) | CN112313243A (es) |
AR (1) | AR115597A1 (es) |
AU (2) | AU2019290163C1 (es) |
BR (1) | BR112020025274A8 (es) |
CA (1) | CA3102629A1 (es) |
CL (2) | CL2020003257A1 (es) |
CO (1) | CO2021000456A2 (es) |
CR (1) | CR20210031A (es) |
DO (1) | DOP2020000250A (es) |
EA (1) | EA202190086A1 (es) |
EC (1) | ECSP21003643A (es) |
GE (1) | GEP20237506B (es) |
IL (1) | IL279363A (es) |
JO (1) | JOP20190150A1 (es) |
MA (1) | MA52967A (es) |
MX (1) | MX2020013726A (es) |
NI (1) | NI202000101A (es) |
PE (1) | PE20211584A1 (es) |
PH (1) | PH12020552187A1 (es) |
SG (1) | SG11202012451WA (es) |
WO (1) | WO2019246349A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100558932B1 (ko) * | 2005-04-21 | 2006-03-10 | 주식회사 엠제이스마트 테크놀러지 | 다공성 세라믹 분리막 제조방법과, 이에 의해 제조되어진 다공성 세라믹 분리막 |
US9822157B2 (en) | 2013-03-15 | 2017-11-21 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
DK3143037T3 (da) | 2014-05-16 | 2021-09-20 | Protagonist Therapeutics Inc | Alpha4beta7-integrin-thioether-peptidantagonister |
EP3169403B1 (en) | 2014-07-17 | 2024-02-14 | Protagonist Therapeutics, Inc. | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
US11753443B2 (en) | 2018-02-08 | 2023-09-12 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
WO2019246405A1 (en) | 2018-06-21 | 2019-12-26 | Merck Sharp & Dohme Corp. | Cyclic polypeptides for pcsk9 inhibition |
EP3810178A4 (en) | 2018-06-21 | 2022-05-04 | Merck Sharp & Dohme Corp. | CYCLIC POLYPEPTIDES TO INHIBIT PCSK9 |
WO2019246387A1 (en) | 2018-06-21 | 2019-12-26 | Ra Pharmaceuticals, Inc. | Cyclic peptides for pcsk9 inhibition |
US11306125B2 (en) | 2018-06-21 | 2022-04-19 | Merck Sharp & Dohme Corp. | PCSK9 antagonists bicyclo-compounds |
US11814444B2 (en) | 2018-06-21 | 2023-11-14 | Ra Pharmaceuticals, Inc. | Cyclic polypeptides for PCSK9 inhibition |
JOP20190150A1 (ar) * | 2018-06-21 | 2019-12-21 | Merck Sharp & Dohme | مركبات مناهضة لـ pcsk9 |
WO2021041770A1 (en) * | 2019-08-30 | 2021-03-04 | Merck Sharp & Dohme Corp. | Pcsk9 antagonist compounds |
US20230144324A1 (en) * | 2019-12-20 | 2023-05-11 | Merck Sharp & Dohme Llc | Pcsk9 antagonist compounds |
JP7441955B2 (ja) | 2020-01-15 | 2024-03-01 | ヤンセン バイオテツク,インコーポレーテツド | インターロイキン23受容体のペプチド阻害剤および炎症性疾患を治療するためのその使用 |
MX2023005994A (es) | 2020-11-20 | 2023-08-11 | Janssen Pharmaceutica Nv | Composiciones de inhibidores peptidicos del receptor de interleucina-23. |
US11932705B2 (en) | 2020-12-18 | 2024-03-19 | Merck Sharp & Dohme Llc | Cyclic polypeptides for PCSK9 inhibition |
KR20240050369A (ko) | 2021-08-19 | 2024-04-18 | 머크 샤프 앤드 돔 엘엘씨 | Pcsk9 활성과 관련된 상태를 치료하기 위한 화합물 |
US20230406885A1 (en) | 2022-06-15 | 2023-12-21 | Merck Sharp & Dohme Llc | Cyclic peptides for trapping interleukin-1 beta |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4393046A (en) | 1981-01-30 | 1983-07-12 | Merck & Co., Inc. | Combination of thiopeptin and other related sulfur-containing cyclic polypeptide antibiotics with rumen-active diimides to improve ruminant feed efficiency |
DE3841520A1 (de) | 1988-12-09 | 1990-06-13 | Hoechst Ag | Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
US5104869A (en) | 1989-10-11 | 1992-04-14 | American Cyanamid Company | Renin inhibitors |
US5114937A (en) | 1989-11-28 | 1992-05-19 | Warner-Lambert Company | Renin inhibiting nonpeptides |
US5095119A (en) | 1990-03-08 | 1992-03-10 | American Home Products Corporation | Renin inhibitors |
AU6691798A (en) | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
AU6452098A (en) | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
EP0970095B1 (en) | 1997-03-07 | 2003-10-29 | Metabasis Therapeutics, Inc. | Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase |
DE69910045T2 (de) | 1998-09-09 | 2004-04-22 | Metabasis Therapeutics Inc., San Diego | Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren |
JP2004513076A (ja) | 2000-07-25 | 2004-04-30 | メルク エンド カムパニー インコーポレーテッド | 糖尿病治療で有用なn−置換インドール類 |
US6852738B2 (en) | 2001-01-30 | 2005-02-08 | Merck & Co., Inc. | Acyl sulfamides for treatment of obesity, diabetes and lipid disorders |
AR040241A1 (es) | 2002-06-10 | 2005-03-23 | Merck & Co Inc | Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia |
NZ538031A (en) | 2002-08-29 | 2007-10-26 | Merck & Co Inc | Indoles having anti-diabetic activity |
EP1546142A4 (en) | 2002-08-29 | 2007-10-17 | Merck & Co Inc | INDOLES HAVING ANTIDIABETIC EFFECT |
JP2007504285A (ja) | 2003-01-17 | 2007-03-01 | メルク エンド カムパニー インコーポレーテッド | N−シクロヘキシルアミノカルボニルベンゼンスルホンアミド誘導体 |
WO2008063382A2 (en) | 2006-11-07 | 2008-05-29 | Merck & Co., Inc. | Antagonists of pcsk9 |
EP2170883A1 (en) | 2007-06-28 | 2010-04-07 | Merck Frosst Canada Ltd. | Substituted fused pyrimidines as antagonists of gpr105 activity |
CN101743616B (zh) | 2007-06-28 | 2012-02-22 | 株式会社半导体能源研究所 | 半导体装置的制造方法 |
US20110301079A1 (en) | 2007-09-21 | 2011-12-08 | Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Neuromedin u receptor agonists and uses thereof |
UY32690A (es) | 2009-06-08 | 2011-01-31 | Astrazeneca Ab | Péptidos específicos para receptores de melanocortina |
WO2011037791A1 (en) | 2009-09-25 | 2011-03-31 | Merck Sharp & Dohme Corp. | Antagonists of pcsk9 |
CA2813049A1 (en) | 2010-09-23 | 2012-03-29 | The Trustees Of The University Of Pennsylvania | Modified compstatin with improved stability and binding properties |
MX2013007497A (es) | 2010-12-28 | 2013-08-01 | Cadila Healthcare Ltd | Compuestos heterociclicos adecuados para el tratamiento de dislipidemia. |
BR112013032667A2 (pt) * | 2011-06-20 | 2017-12-12 | Genentech Inc | polipeptídeo de ligação a pcsk9, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o polipeptídeo, composição farmacêutica, método de redução do nível de colesterol ldl em um sujeito, método de tratamento de disfunção relacionada ao colesterol em um sujeito, método de tratamento de hipercolesterolemia em um sujeito, método de inibição da ligação de pcsk9 a ldlr e método de detecção da proteína pcsk9 em uma amostra |
NZ747501A (en) | 2011-10-27 | 2020-05-29 | Massachusetts Inst Technology | Amino acid derivatives functionalized on the n-terminal capable of forming drug encapsulating microspheres |
WO2013138340A1 (en) | 2012-03-13 | 2013-09-19 | Tensive Controls Inc. | Melanocortin analogs having enhanced activity and transport |
EP2850095B1 (en) | 2012-05-17 | 2019-10-09 | RA Pharmaceuticals, Inc. | Peptide and peptidomimetic inhibitors |
RU2015142437A (ru) * | 2013-03-14 | 2017-04-27 | Дайити Санкио Ко., Лтд | Новые связывающие белки для pcsk9 |
AU2014237312B2 (en) | 2013-03-15 | 2019-03-28 | Shifa Biomedical Corporation | Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases |
WO2016119067A1 (en) | 2015-01-30 | 2016-08-04 | Pronasci Inc. | Peptides derived from human pcsk9 catalytic domain and uses there of for promoting ldl-r activity |
EP3442991A4 (en) | 2016-04-15 | 2019-11-20 | RA Pharmaceuticals, Inc. | RAS-BINDING PEPTIDES AND METHODS OF USE |
EP3474875A1 (en) | 2016-06-24 | 2019-05-01 | H. Hoffnabb-La Roche Ag | Compositions and methods for treating cardiovascular disease |
US10577357B2 (en) | 2016-09-19 | 2020-03-03 | The Texas A&M University System | Inhibitors of LDLR-PCSK9 protein-protein interaction and methods of their use |
CN107158002B (zh) * | 2017-07-01 | 2020-06-16 | 维亚生物科技(上海)有限公司 | 苄撑巴比妥类化合物在作为pcsk9拮抗剂和降低低密度脂蛋白中的应用 |
US11814444B2 (en) | 2018-06-21 | 2023-11-14 | Ra Pharmaceuticals, Inc. | Cyclic polypeptides for PCSK9 inhibition |
EP3810178A4 (en) | 2018-06-21 | 2022-05-04 | Merck Sharp & Dohme Corp. | CYCLIC POLYPEPTIDES TO INHIBIT PCSK9 |
WO2019246387A1 (en) | 2018-06-21 | 2019-12-26 | Ra Pharmaceuticals, Inc. | Cyclic peptides for pcsk9 inhibition |
WO2019246405A1 (en) | 2018-06-21 | 2019-12-26 | Merck Sharp & Dohme Corp. | Cyclic polypeptides for pcsk9 inhibition |
US11306125B2 (en) | 2018-06-21 | 2022-04-19 | Merck Sharp & Dohme Corp. | PCSK9 antagonists bicyclo-compounds |
JOP20190150A1 (ar) | 2018-06-21 | 2019-12-21 | Merck Sharp & Dohme | مركبات مناهضة لـ pcsk9 |
WO2021041770A1 (en) | 2019-08-30 | 2021-03-04 | Merck Sharp & Dohme Corp. | Pcsk9 antagonist compounds |
-
2018
- 2018-06-21 JO JOP/2019/0150A patent/JOP20190150A1/ar unknown
-
2019
- 2019-06-20 KR KR1020217001723A patent/KR20210024035A/ko active Search and Examination
- 2019-06-20 BR BR112020025274A patent/BR112020025274A8/pt unknown
- 2019-06-20 GE GEAP201915540A patent/GEP20237506B/en unknown
- 2019-06-20 US US16/446,940 patent/US11427616B2/en active Active
- 2019-06-20 EP EP19739801.9A patent/EP3810626A1/en active Pending
- 2019-06-20 MA MA052967A patent/MA52967A/fr unknown
- 2019-06-20 JP JP2020570427A patent/JP7112531B2/ja active Active
- 2019-06-20 MX MX2020013726A patent/MX2020013726A/es unknown
- 2019-06-20 CA CA3102629A patent/CA3102629A1/en active Pending
- 2019-06-20 CR CR20210031A patent/CR20210031A/es unknown
- 2019-06-20 CN CN201980041438.5A patent/CN112313243A/zh active Pending
- 2019-06-20 AU AU2019290163A patent/AU2019290163C1/en active Active
- 2019-06-20 PE PE2020002109A patent/PE20211584A1/es unknown
- 2019-06-20 EA EA202190086A patent/EA202190086A1/ru unknown
- 2019-06-20 SG SG11202012451WA patent/SG11202012451WA/en unknown
- 2019-06-20 WO PCT/US2019/038155 patent/WO2019246349A1/en unknown
- 2019-06-21 AR ARP190101718A patent/AR115597A1/es unknown
-
2020
- 2020-12-10 IL IL279363A patent/IL279363A/en unknown
- 2020-12-14 NI NI202000101A patent/NI202000101A/es unknown
- 2020-12-16 PH PH12020552187A patent/PH12020552187A1/en unknown
- 2020-12-16 CL CL2020003257A patent/CL2020003257A1/es unknown
- 2020-12-17 DO DO2020000250A patent/DOP2020000250A/es unknown
-
2021
- 2021-01-18 EC ECSENADI20213643A patent/ECSP21003643A/es unknown
- 2021-01-19 CO CONC2021/0000456A patent/CO2021000456A2/es unknown
-
2022
- 2022-01-05 CL CL2022000027A patent/CL2022000027A1/es unknown
- 2022-06-30 US US17/854,379 patent/US20230159592A1/en active Pending
- 2022-07-22 JP JP2022117123A patent/JP2022141879A/ja active Pending
- 2022-10-25 AU AU2022259744A patent/AU2022259744A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2020000250A (es) | Compuestos antagonistas de la pcsk9 | |
CY1122730T1 (el) | 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων | |
CY1123476T1 (el) | Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων | |
CY1125613T1 (el) | 4-ιμιδαζοπυριδαζιν-1-υλ-βενζαμιδια και 4- ιμιδαζοτριαζιν-1-υλ-βενζαμιδια ως αναστολεις βτκ | |
CY1123627T1 (el) | Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου | |
CY1117183T1 (el) | Διακλαδισμενα παραγωγα 3-φαινυλοπροπιονικου οξεος και η χρηση τους | |
EA201800064A1 (ru) | 1,1,1-трифтор-3-гидроксипропан-2-ил карбаматные производные и 1,1,1-трифтор-4-гидроксибутан-2-ил карбаматные производные в качестве ингибиторов magl | |
EA201490647A1 (ru) | Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции | |
UY34974A (es) | Piridazina 1,4 disustituida, análogos de la misma y métodos para tratar las enfermedades relacionadas con deficiencia del smn | |
CO6531452A2 (es) | Piperidinas sustituidas que aumentan la actividad de p53 y sus usos | |
BR112014018959A8 (pt) | Compostos, composições farmacêuticas, utilizações de um composto e métodos para o tratamento do câncer | |
CU24330B1 (es) | Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral) | |
BR112019001980A2 (pt) | inibidor de ido1 e método de preparação e aplicação do mesmo | |
UY37379A (es) | Derivados de n-(piridin-2-il)piridina-sulfonamida y su uso en el tratamiento de enfermedades | |
EA201792072A3 (ru) | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения | |
EA201890532A1 (ru) | Новые аннелированные бензамиды | |
PE20142337A1 (es) | Sales de 5-[(1r)-2-({2-[4-(2,2-difluoro-2-feniletoxi)fenil]etil}amino)-1-hidroxietil]-8-hidroxiquinolin-2(1h)-ona | |
AR109168A1 (es) | Sales de derivados de 2,6-dimetilpirimidona y sus usos | |
PE20151607A1 (es) | Formulaciones de compuestos organicos | |
CO2017003994A2 (es) | Derivados de nucleósidos sustituidos con 4’-vinilo como inhibidores de la replicación del arn del virus respiratorio sincitial | |
BR112016010253A8 (pt) | sais de 1-(3-metil-2-oxo-2,3-di-hidro-1,3-benzoxazol-6-il)-2,4-dioxo-3-[(1r)- 4-(trifluorometil)-2,3-di-hidro-1h-inden-1-il]-1,2,3,4-tetra-hidropirimidin-5-ácido carboxílico | |
BR112015024897A2 (pt) | derivado de fenila | |
AR088845A1 (es) | Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel | |
UY30705A1 (es) | Sulfonamidas sustituidas | |
AR119864A1 (es) | Compuestos antagonistas de pcsk9 |